Free Shipping on orders over US$39.99 How to make these links

Xishan Technology completed a series D financing of more than 100 million yuan, and the investors were Sinopharm Investment and Jinhe Capital

【 Beijing】Reported on December 13

Recently, Xishan Technology, a digital minimally invasive surgical equipment and consumables research and development manufacturer, announced that it has completed a D round of strategic financing of more than 100 million yuan. This round of financing was jointly completed by industrial investors Sinopharm Investment and Jinhe Capital.

It is understood that the proceeds from this round of financing will be used for new product development, clinical research registration and market transformation, and continue to build a leading domestic and international leading brand of minimally invasive medical devices.

Guo Yijun, Chairman of Xishan Technology, said: “Thanks to Sinopharm Investment and Jinhe Capital for their support and encouragement to Xishan Technology. I believe that with the help of the two industry investors, Xishan Technology will adhere to the strategy of’provider of minimally invasive surgery tools’ overall solution. Positioning, rapid development, bravely climbing the peak, and contributing to the localization of minimally invasive surgical tools.”

Zhang Weiya, head of the Sinopharm Investment Industry Investment Department, said: “my country’s minimally invasive surgical device market is in a period of rapid growth. As an important part of the surgical power system, it has the characteristics of large capital investment, long research and development cycles, and high competition barriers. Xishan Technology Mastering core technologies such as motors and precision tools, product quality and product matrix are in the first echelon of domestic surgical power. Sinopharm Investment is optimistic about the development of Xishan Technology in the field of minimally invasive surgery. After this strategic investment, it will fully rely on the entire industry chain of Sinopharm Group Platform resources continue to empower Xishan Technology, assist the development of domestic brands, and promote the process of domestic substitution in the field of minimally invasive surgery.”

Mr. Hao Bixi, co-founder of Jinhe Capital, said: “China’s minimally invasive surgical instrument market is growing rapidly and has a large room for import substitution. Xishan Technology’s management team has both keen market insight and strategic layout capabilities, and a series of products developed independently It has been highly recognized by clinical experts, and its comprehensive strength is at the forefront of the industry. Jinhe Capital is very optimistic about Xishan Technology’s profound technical background and platform-based development ideas. After this strategic investment, we will fully integrate industrial resources and continue to empower Xishan Technology helps companies become more well-known national brands in the industry.”

Founded in 1999, Chongqing Xishan Technology Co., Ltd. is a high-tech enterprise focusing on the research and development, manufacturing and sales of minimally invasive surgical medical equipment software and hardware. The company’s main products are organized around three major technology platforms and seven major business directions, including surgical power equipment and consumables for neurosurgery, ENT, orthopedics, and breast surgery departments.

Since its establishment, Xishan Technology has conducted technical research and product development around surgical diagnosis and guidance and surgical treatment, and has built a “1+2” ​​product group, committed to becoming a world-class minimally invasive medical device brand. At the same time, it has independently mastered a number of core technologies and key manufacturing processes, and the number of patent applications has exceeded 900.

It is reported that Xishan Technology attaches great importance to R&D investment. The R&D investment in the past three years has accounted for more than 10%. A number of technologies are industry-leading, and as the first drafting unit, a number of pharmaceutical industry standards have been formulated.

The Links:   NL8060BC31-17 MDF250A20M

We will be happy to hear your thoughts

Leave a reply

House idea
Enable registration in settings - general
Compare items
  • Total (0)
Shopping cart